Clinical trial NCT06167447: Evaluation of the Presence and Effects of Kinesiophobia in Multiple Sclerosis
Official title: Evaluation Of The Existence Of Kinesiophobia In Patients With Multiple Sclerosis; Effect Of Kinesiophobia On Physical Activity,Functional Status, Quality Of Life and Depression
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Multiple Sclerosis
Kinesiophobia
Keywords: Multiple sclerosis
kinesiophobia
fear of movement
Lead sponsor: Gazi University
Sponsor class: OTHER
First posted: 2023-12-12
Enrollment: 90
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: A total of 90 people, 45 patients and 45 healthy controls, who applied to the Gazi University Medical School PM\&R and Neurology multiple sclerosis outpatient clinic between the ages of 18-65, were included in the study.

Brief summary: The aim of this study was to evaluate the presence of kinesiophobia in multiple sclerosis and to investigate the effect of kinesiophobia on physical activity, functional status, quality of life and depression.

Detailed description: 90 people, including 45 patients and 45 healthy control groups, were included in the study. Demographic data of all participants were recorded. Tampa Scale of Kinesiophobia (TSK), Beck Depression Inventory (BDI), Quality of Life Scale Short Form-36 (SF-36), International Physical Activity Questionnaire Short Form (IPAQ-SF), Functional Ambulation Classification (FAS), in addition to Multiple Sclerosis group, Functional Independence Measure (FIM), Expanded Disability Status Scale (EDSS) were implemented.

Eligibility criteria: Inclusion Criteria:

* Having a definitive diagnosis of MS according to the 2017 Revised McDonald Diagnostic Criteria
* Expanded Disability Status Scale (EDSS) score between 0-6.5
* Be between the ages of 18-65
* Volunteering to participate in the study

Exclusion Criteria:

* Having orthopedic, psychiatric and other chronic diseases other than MS that may affect physical and cognitive status
* Expanded Disability Status Scale (EDSS) score \>6.5
* Being in the MS attack period

Primary outcomes:
measure: Tampa Scale of Kinesiophobia
timeFrame: through study completion, an average of 6 months.
Secondary outcomes:
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Bilge Nur Kılınç
Study officials:
affiliation: Gazi University
name: Bilge Nur Kilinc
role: STUDY_DIRECTOR
References:
citation: Dobson R, Giovannoni G. Multiple sclerosis - a review. Eur J Neurol. 2019 Jan;26(1):27-40. doi: 10.1111/ene.13819. Epub 2018 Nov 18.
citation: Zalc B. One hundred and fifty years ago Charcot reported multiple sclerosis as a new neurological disease. Brain. 2018 Dec 1;141(12):3482-3488. doi: 10.1093/brain/awy287. No abstract available.
citation: Walton C, King R, Rechtman L, Kaye W, Leray E, Marrie RA, Robertson N, La Rocca N, Uitdehaag B, van der Mei I, Wallin M, Helme A, Angood Napier C, Rijke N, Baneke P. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult Scler. 2020 Dec;26(14):1816-1821. doi: 10.1177/1352458520970841. Epub 2020 Nov 11.
citation: Kesselring J, Beer S. Symptomatic therapy and neurorehabilitation in multiple sclerosis. Lancet Neurol. 2005 Oct;4(10):643-52. doi: 10.1016/S1474-4422(05)70193-9.